177Lu-Rituximab is the Lutetium-177 labeled analogue of 131I-Tositumomab (131I-Bexxar) for the treatment of NHL. This drug is developed at the Bushehr University of Medical Sciences (BUMS), Bushehr, Iran, and the Department of Nuclear medicine, Klinikum Westfalen, Dortmund, Germany.
The first clinical data were published in October 2021.

Target/Mechanism: CD20

Carrier/Ligand: Rituximab

Radiation Type: beta electrons (β^–)